Unknown PHASE2 INTERVENTIONAL 2-arm NCT02551042

CSL Behring Sclero XIII

A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis

Sponsor: CSL Behring

Conditions Systemic Sclerosis

Interventions 0.9% sodium chloride Fibrogammin®P, coagulation factor XIII concentrate (Human)

Updated 7 times since 2017 Last updated: May 27, 2016 Started: Sep 30, 2015 Primary completion: Sep 30, 2016 Completion: Sep 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Systemic Sclerosis, this trial is ongoing. The trial is conducted by CSL Behring and has accumulated 7 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Oct 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Oct 2018 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSL Behring
University College, London

Data source: University College, London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom